SAVA News and Press, Cassava Sciences Inc. From 11/07/23

2023-11-07 09:47:25 ET More on Cassava Sciences Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct ...

Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's. Over 1,900 patients randomized in on-going Phase 3 trials. Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected appro...

2023-11-06 10:11:02 ET More on Cassava Sciences Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct ...

1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024. Top-line results for on-going, 76-week Phase 3 trial expected approximately ...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Cassava Sciences Inc. (SAVA) is expected to report $-0.9 for Q3 2023

2023-11-03 03:55:48 ET Summary Cassava Sciences' presentation at the CTAD Conference undermines its claim that simufilam is an effective treatment for Alzheimer's Disease. The drug appears to have little to no effect on moderate Alzheimer's disease and only better for a year than ...

2023-10-30 03:30:35 ET Summary Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating ...

2023-10-25 13:59:34 ET More on Cassava Sciences Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims Cassava Sciences: Update Following Leaked CUNY Report, Fundamentals Remain Unchanged Cassava Sciences: Unconvincing Open Label Studies, Upcomin...

Safety Finding Based on Blinded MRI Brain Data at Week 40 ARIA is a Known Risk Factor for Anti-Amyloid Antibody Drugs MRI Data Presented at the 16 th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: ...